Prostate Cancer Center Trials Consortium: CRO Study

/Prostate Cancer Center Trials Consortium: CRO Study

Prostate Cancer Center Trials Consortium: CRO Study

The Prostate Cancer Clinical Trials Consortium (PCCTC) is a collaborative between the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP), designed to fill the gaps identified in prostate cancer clinical research. The PCCTC is internationally recognized as the nation’s leading multicenter clinical research organization specializing in cutting-edge prostate cancer research, with a network of over 20 academic institutions nationwide. PCCTC members work together on a targeted mission: to design, implement, and complete hypothesis- driven early phase trials in prostate cancer, translating scientific discoveries to improved standards of care.

The Goal
PCCTC coordinates the intricate details of regulatory document management throughout each trial, serving as a single point of contact for industry partners and investigators. “The complexities of ensuring the accuracy and compliance of study documents cannot be underestimated,” comments PCCTC CEO Jake Vinson. In June of 2016, PCCTC decided they wanted to expand and enhance their trial management capabilities, choosing eBinders to help them reach their goal.

How eBinders Helps
eBinders two sided portal for eTMF and eISV helps via— 

  • Faster Startup: The eBinder Suite helps investigator teams take on more studies and reduce compliance risks, so that new therapies can reach those in need, sooner.
  • Site-Work Reduction: Wasteful paper chores are converted into one-click tasks—reducing site work and delivering insights to study sponsors faster.
  • Efficiency For All: Management tools like the shared real-time dashboard allows everyone to stay on the same page, making research more efficient for both sites and sponsors at the same time.

“Deploying Florence’s eTMF within the PCCTC has the potential to shorten the time it takes to bring safe and effective products our investigators develop to market,” says Vinson.

Latest posts by Richard Walsh (see all)


    About the Author: